Lexaria Bioscience Corp
LEXX0.874USD
+0.024+2.82%
Market hours （ET）Quotes delayed by 15 min
17.01MMarket Cap
LossP/E TTM
More Details of Lexaria Bioscience Corp Company
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.
Company Info
Ticker SymbolLEXX
Company nameLexaria Bioscience Corp
IPO dateOct 28, 2009
CEOMr. Richard Christopher
Number of employees7
Security typeOrdinary Share
Fiscal year-endOct 28
Address100 - 740 Mccurdy Road
CityKELOWNA
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeV1X 2P7
Phone12507656424
Websitehttps://www.lexariabioscience.com/
Ticker SymbolLEXX
IPO dateOct 28, 2009
CEOMr. Richard Christopher
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
627.96K
+18.94%
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
+9.94%
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
-62.33%
Dr. Catherine C. Turkel, Ph.D.
Dr. Catherine C. Turkel, Ph.D.
Independent Director
Independent Director
3.10K
-61.73%
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Ted Mckechnie
Mr. Ted Mckechnie
Independent Director
Independent Director
--
--
Mr. Albert (Al) Reese, Jr.
Mr. Albert (Al) Reese, Jr.
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Shankman, CPA
Mr. Michael (Mike) Shankman, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher A. (Chris) Bunka
Mr. Christopher A. (Chris) Bunka
Chairman of the Board
Chairman of the Board
627.96K
+18.94%
Mr. John Martin Docherty
Mr. John Martin Docherty
President, Director
President, Director
59.45K
+9.94%
Mr. Nicholas W. (Nick) Baxter
Mr. Nicholas W. (Nick) Baxter
Independent Director
Independent Director
11.00K
-62.33%
Dr. Catherine C. Turkel, Ph.D.
Dr. Catherine C. Turkel, Ph.D.
Independent Director
Independent Director
3.10K
-61.73%
Mr. Richard Christopher
Mr. Richard Christopher
Chief Executive Officer
Chief Executive Officer
--
--
Mr. Ted Mckechnie
Mr. Ted Mckechnie
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bunka (Christopher A)
3.58%
Boos (Wayne W)
3.07%
Invenomic Capital Management LP
2.81%
Geode Capital Management, L.L.C.
0.88%
TD Securities, Inc.
0.66%
Other
89.00%
Shareholders
Shareholders
Proportion
Bunka (Christopher A)
3.58%
Boos (Wayne W)
3.07%
Invenomic Capital Management LP
2.81%
Geode Capital Management, L.L.C.
0.88%
TD Securities, Inc.
0.66%
Other
89.00%
Shareholder Types
Shareholders
Proportion
Individual Investor
7.01%
Hedge Fund
2.82%
Investment Advisor/Hedge Fund
1.83%
Investment Advisor
1.04%
Research Firm
0.68%
Other
86.63%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
55
2.62M
13.81%
-923.25K
2025Q1
58
2.67M
14.13%
-877.04K
2024Q4
57
2.74M
15.64%
-1.58M
2024Q3
53
2.33M
14.32%
-1.90M
2024Q2
51
3.71M
26.13%
+1.31M
2024Q1
48
2.53M
20.12%
-589.59K
2023Q4
42
2.77M
29.73%
-632.85K
2023Q3
39
3.31M
38.25%
+947.07K
2023Q2
37
2.00M
33.36%
-102.20K
2023Q1
40
1.78M
29.80%
-315.18K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bunka (Christopher A)
627.96K
3.58%
+100.00K
+18.94%
Jan 07, 2025
Boos (Wayne W)
600.00K
3.08%
-315.43K
-34.46%
Aug 31, 2024
Invenomic Capital Management LP
549.95K
2.82%
+139.22K
+33.89%
Mar 31, 2025
Geode Capital Management, L.L.C.
172.46K
0.89%
+5.78K
+3.47%
Mar 31, 2025
TD Securities, Inc.
130.03K
0.67%
+130.03K
--
Mar 31, 2025
The Vanguard Group, Inc.
127.87K
0.66%
+438.00
+0.34%
Mar 31, 2025
Christopher (Richard C)
50.00K
0.29%
+50.00K
--
Dec 03, 2024
Raymond James Financial Services Advisors, Inc.
61.25K
0.31%
+610.00
+1.01%
Mar 31, 2025
Docherty (John Martin)
54.08K
0.28%
--
--
Nov 18, 2024
State Street Global Advisors (US)
39.30K
0.2%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
